Disclaimer: This information is for educational and informational purposes only and does not constitute medical advice. It is intended for use by healthcare professionals as a supplementary resource. Clinical decisions must always be made based on the individual patient's condition, available clinical data, and the healthcare provider's professional judgment. Consult official guidelines and expert consensus for the most current and definitive recommendations.

Management Of Dka

Overview

• Definition: Diabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes mellitus characterized by uncontrolled hyperglycemia, metabolic acidosis, and increased total body ketone concentration due to absolute or relative insulin deficiency, often coupled with an increase in counter-regulatory hormones. Diagnostic Criteria (American Diabetes Association - ADA):

  • Hyperglycemia: Plasma glucose >250 mg/dL (13.9 mmol/L)
  • Metabolic Acidosis: Arterial pH <7.3 and/or serum bicarbonate <18 mEq/L
  • Ketosis: Presence of ketones in blood (serum beta-hydroxybutyrate $\ge$ 3.0 mmol/L) or urine (moderate to large).
  • Anion Gap: Elevated (>10-12 mEq/L), calculated as Na+ - (Cl- + HCO3-).

• Epidemiology:

  • Approximately 1-5% of patients with Type 1 Diabetes Mellitus (T1DM) experience DKA annually.
  • Incidence is rising globally, partly due to increased T1DM incidence and possibly delayed diagnosis.
  • More common in T1DM, but can occur in T2DM (often termed "ketosis-prone T2DM" or "Flatbush diabetes").
  • Leading cause of morbidity and mortality in children and adolescents with T1DM.
  • Common precipitants include infection (pneumonia, UTI), insulin omission/pump failure, new onset diabetes, myocardial infarction, stroke, pancreatitis, certain drugs (e.g., glucocorticoids, atypical antipsychotics, SGLT2 inhibitors).

• Classification: DKA severity is classified based on biochemical parameters:

  Parameter	Mild DKA	Moderate DKA	Severe DKA
  Plasma Glucose	>250 mg/dL (13.9 mmol/L)	>250 mg/dL (13.9 mmol/L)	>250 mg/dL (13.9 mmol/L)
  Arterial pH	7.25 - <7.30	7.00 - <7.25	<7.00
  Bicarbonate	15 - <18 mEq/L	10 - <15 mEq/L	<10 mEq/L
  Serum Ketones	Positive (moderate)	Positive (large)	Positive (large)
  Anion Gap	>10-12 mEq/L	>12 mEq/L	>12 mEq/L
  Mental Status	Alert	Alert/Drowsy	Stupor/Coma

Pathophysiology

• Mechanism: DKA arises from a profound deficiency of insulin, combined with an excess of counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone).

  1. Insulin Deficiency: Leads to decreased glucose uptake by peripheral tissues and increased hepatic glucose production.
     • Hyperglycemia: Due to increased glycogenolysis and gluconeogenesis, and reduced glucose utilization by insulin-sensitive tissues. This results in osmotic diuresis, leading to significant fluid and electrolyte losses (polyuria, polydipsia).
     • Lipolysis: Unrestrained breakdown of triglycerides into free fatty acids (FFAs) in adipose tissue.
     • Ketogenesis: FFAs are transported to the liver, where, in the absence of insulin (which normally inhibits carnitine palmitoyltransferase I, CPT1) and in the presence of high glucagon-to-insulin ratio, they undergo beta-oxidation to produce acetyl-CoA. This excess acetyl-CoA is then converted into ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone).
     • Metabolic Acidosis: Acetoacetate and beta-hydroxybutyrate are strong acids, accumulating in the blood and consuming bicarbonate, leading to a high anion gap metabolic acidosis.
  2. Counter-regulatory Hormone Excess: These hormones exacerbate hyperglycemia by promoting gluconeogenesis and glycogenolysis, and contribute to lipolysis. Catecholamines and cortisol inhibit insulin action at the cellular level.
  3. Electrolyte Derangements: Osmotic diuresis causes losses of sodium, potassium, phosphate, and magnesium. Despite normal or elevated serum potassium levels on admission (due to extracellular shift from acidosis and insulin deficiency), the total body potassium content is depleted. Insulin shifts potassium back into cells.

• Risk Factors:

  • Infection: Most common precipitant (e.g., pneumonia, UTI, gastroenteritis, sepsis).
  • Insulin omission or inadequate dosing: Often due to non-adherence, psychological factors, or insulin pump malfunction.
  • New diagnosis of Type 1 Diabetes: DKA is the initial presentation in 25-40% of T1DM cases.
  • Medical illness/stress: Myocardial infarction, stroke, pancreatitis, trauma, surgery, major emotional stress.
  • Certain medications: Glucocorticoids, thiazide diuretics, sympathomimetics, atypical antipsychotics, SGLT2 inhibitors (can cause euglycemic DKA).
  • Eating disorders or psychiatric illness: Can lead to insulin omission.
  • Alcohol or drug abuse: Can impair self-management and precipitate DKA.

• Protective Factors:

  • Strict adherence to insulin regimen.
  • Appropriate "sick day" management: monitoring blood glucose/ketones, taking extra insulin as needed, maintaining hydration, seeking medical attention early.
  • Diabetes education for patient and family.
  • Regular follow-up with healthcare providers.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:

  • Polyuria: Increased urination due to osmotic diuresis.
  • Polydipsia: Increased thirst secondary to dehydration.
  • Polyphagia/Weight loss: Initial hunger, but later anorexia and weight loss.
  • Nausea, Vomiting, Abdominal Pain: Common, can mimic acute abdomen.
  • Fatigue, Weakness: Due to dehydration, electrolyte imbalance, and metabolic acidosis.
  • Kussmaul respirations: Deep, rapid breathing, the body's compensatory mechanism to blow off CO2 and reduce acidosis.
  • Fruity breath odor: Characteristic smell of acetone.
  • Altered Mental Status: From lethargy to coma, depending on severity of dehydration, acidosis, and hyperosmolality.

• Early Signs:

  • Polyuria, polydipsia.
  • Generalized weakness, fatigue.
  • Headache.
  • Blurred vision.

• Advanced Signs:

  • Profound dehydration (tachycardia, hypotension, dry mucous membranes, decreased skin turgor).
  • Kussmaul respirations.
  • Significant abdominal pain, nausea, vomiting.
  • Obtundation, stupor, or coma.

• Atypical Presentations:

  • Euglycemic DKA: Defined as DKA with blood glucose <250 mg/dL (13.9 mmol/L). Can occur in patients taking SGLT2 inhibitors, those with limited oral intake, or during pregnancy. Requires high index of suspicion as hyperglycemia is absent.
  • DKA in Type 2 Diabetes (Ketosis-prone T2DM): Often presenting with DKA as the first manifestation of diabetes or during severe stress. May initially require insulin, but many can transition to oral agents or diet/exercise alone after recovery.
  • Normal pH DKA: Rare, where acidosis is initially buffered, but significant ketosis and elevated anion gap are present.

Physical Examination

• Inspection:

  • Signs of Dehydration: Dry mucous membranes, decreased skin turgor (especially in elderly), sunken eyeballs, absence of tears.
  • Respiratory pattern: Kussmaul respirations (deep and rapid).
  • Breath odor: Fruity (acetone) or alcoholic.
  • General appearance: Ill-appearing, lethargic, weak.
  • Signs of precipitating cause: Fever, cellulitis, surgical wound infection, signs of stroke or MI.

• Palpation:

  • Pulse: Tachycardia (due to dehydration and stress).
  • Blood Pressure: Orthostatic hypotension or frank hypotension (indicates severe dehydration/shock).
  • Abdomen: Tenderness, guarding, or rigidity (abdominal pain is common, consider differential diagnosis for acute abdomen).
  • Skin: Cool extremities (shock).

• Special Tests:

  • Orthostatic Vital Signs: Significant drop in BP or increase in HR with standing indicates hypovolemia.
  • Neurological Exam: Assess level of consciousness (Glasgow Coma Scale), pupillary response, and focal neurological deficits (especially if cerebral edema is suspected, although rare).

Diagnostic Approach

History Taking

• Key Questions:

  • Onset and duration of symptoms: Polyuria, polydipsia, weight loss, nausea, vomiting, abdominal pain, fatigue, altered mental status.
  • Diabetes history: Type of diabetes, duration, usual insulin regimen (type, dose, frequency), last insulin dose taken, insulin pump use/issues.
  • Precipitating factors: Recent illness (fever, cough, urinary symptoms, GI symptoms), missed insulin doses, non-adherence, new medications, substance abuse, psychological stress.
  • Prior DKA episodes: Frequency, causes, management, patient's understanding of sick day rules.
  • Comorbidities: Heart failure, renal disease, hypertension, other endocrine disorders.
  • Current medications: Especially SGLT2 inhibitors, corticosteroids, diuretics.

• Red Flags:

  • Altered mental status (lethargy, stupor, coma).
  • Signs of severe dehydration (hypotension, poor perfusion).
  • Severe respiratory distress.
  • Persistent vomiting.
  • Severe abdominal pain that does not improve with initial management (consider other causes).

Laboratory Tests

• First-Line:

  • Capillary Blood Glucose (Point-of-Care): Rapid assessment of hyperglycemia.
  • Urinalysis: Dipstick for glucose and ketones.
  • Arterial Blood Gas (ABG) or Venous Blood Gas (VBG):
    • pH: To confirm acidosis and severity. VBG pH is typically 0.02-0.04 units lower than ABG.
    • Bicarbonate (HCO3): To confirm metabolic acidosis.
    • PCO2: To assess respiratory compensation.
  • Serum Electrolytes: Sodium, potassium, chloride, bicarbonate.
    • Corrected Sodium: Measured Na + 0.016 * (glucose in mg/dL - 100). Important as hyperglycemia causes dilutional hyponatremia.
    • Anion Gap: Na - (Cl + HCO3). An elevated anion gap (>10-12 mEq/L) is crucial for diagnosis and monitoring resolution.
  • Blood Urea Nitrogen (BUN) and Creatinine (Cr): To assess renal function and degree of dehydration.
  • Serum Osmolality: Calculated as 2*Na + glucose/18 + BUN/2.8. Usually elevated in DKA.
  • Complete Blood Count (CBC) with differential: Leukocytosis is common due to stress, but marked leukocytosis may indicate infection.
  • C-reactive protein (CRP) / Procalcitonin: To aid in identifying underlying infection if suspected.

• Confirmatory:

  • Serum Beta-Hydroxybutyrate (BHB): The predominant ketone body in DKA, most accurate measure of ketosis and severity. Levels $\ge$ 3.0 mmol/L are diagnostic. (Urine ketones are less reliable as they primarily detect acetoacetate and can remain positive after clinical improvement).

• Monitoring:

  • Capillary Blood Glucose: Hourly or every 1-2 hours.
  • Serum Electrolytes (Na, K, Bicarbonate): Every 2-4 hours, including anion gap calculation.
  • Serum Beta-Hydroxybutyrate: Every 4-6 hours (or with electrolytes) to track ketosis resolution.
  • Arterial/Venous pH: Every 2-4 hours initially, until acidosis resolves.
  • BUN/Creatinine: As needed to monitor renal function.
  • Fluid Balance: Strict intake and output, daily weights.

Imaging

• Recommended:

  • Chest X-ray (CXR): If signs of respiratory infection (cough, fever, dyspnea, abnormal lung sounds) are present.
  • Electrocardiogram (ECG): To evaluate for cardiac ischemia (as a precipitating cause or complication) and to assess for hyperkalemia or hypokalemia (peaked T waves in hyperkalemia, flattened T waves/U waves in hypokalemia).

• Advanced:

  • CT scan of abdomen/pelvis: If severe abdominal pain is unresponsive to initial DKA treatment or if an intra-abdominal infection (e.g., pancreatitis, appendicitis, cholecystitis) is strongly suspected.
  • CT scan of head: If there is sudden, severe worsening of neurological status, focal neurological deficits, or persistent coma, to rule out cerebral edema (rare but critical complication, especially in children).

Management

DKA management requires aggressive and systematic treatment of fluid depletion, hyperglycemia, ketosis, and electrolyte imbalances, as well as identification and treatment of the precipitating cause. Treatment should ideally be initiated in an intensive care unit (ICU) or a high-dependency unit.

Acute Management

Goal: Restore fluid balance, normalize glucose and ketone levels, correct acidosis and electrolyte abnormalities, identify and treat precipitating factors.

• Immediate (First Hour):

  1. Airway, Breathing, Circulation (ABC):
     • Assess airway patency, ensure adequate ventilation.
     • Supplemental oxygen if SpO2 <92% or signs of respiratory distress.
     • Establish two large-bore intravenous (IV) accesses.
  2. Fluid Resuscitation: Most critical initial step.
     • Adults: IV Normal Saline (0.9% NaCl)
       • Initial bolus: 1-1.5 L/hour (or 15-20 mL/kg/hr) over the first hour.
       • Rationale: Rehydrates the patient, improves renal perfusion, and lowers blood glucose by enhancing urinary glucose excretion.
     • Pediatrics: 10-20 mL/kg over the first hour. (Caution in pediatrics due to cerebral edema risk, usually max 10 mL/kg/hr).
  3. Laboratory Studies: Send initial bloods (glucose, electrolytes, ABG/VBG, ketones, BUN/Cr, CBC, osmolality).
  4. Urine Catheter: Consider for comatose or anuric patients to monitor urine output.

• Stabilization (Early Management Priorities - ongoing after first hour):

  1. Fluid Therapy:

     • After initial bolus, assess hydration status, urine output, and electrolyte levels (especially corrected Na).
     • Adults:
       • If corrected Na is normal or high: Switch to 0.45% NaCl (half-normal saline) at 250-500 mL/hour. Rationale: Provides free water to correct hyperosmolality.
       • If corrected Na is low: Continue 0.9% NaCl at 250-500 mL/hour.
       • When plasma glucose reaches 200 mg/dL (11.1 mmol/L): Add dextrose (D5W or D10W) to IV fluids (e.g., D5 0.45% NaCl) at 150-250 mL/hour. Rationale: Prevents hypoglycemia and allows continued insulin infusion at a rate that resolves ketosis and acidosis, which usually takes longer than glucose normalization.
     • Pediatrics: After initial bolus, continue with 0.45% NaCl at 1.5-2 times maintenance fluid rate, with careful consideration of total fluid deficit and replacement (e.g., replace remaining 80% of deficit over 24-48 hours). Add dextrose (D5W or D10W) when glucose reaches 250-300 mg/dL (13.9-16.7 mmol/L).

  2. Insulin Therapy:

     • Begin insulin infusion ONLY AFTER initial fluid resuscitation has started and serum potassium is $\ge$ 3.3 mEq/L.
       • Rationale: Insulin drives potassium into cells, potentially worsening hypokalemia. Correcting hypokalemia first is crucial.
     • Adults: IV Regular Insulin infusion at 0.1 units/kg/hour.
       • Example: For a 70 kg patient, 7 units/hour.
       • Target: Glucose decrease of 50-75 mg/dL/hour (2.8-4.2 mmol/L/hour). If glucose does not fall at this rate, double the insulin dose.
     • Pediatrics: IV Regular Insulin infusion at 0.1 units/kg/hour.
     • Mild DKA: In some settings, mild DKA may be managed with subcutaneous rapid-acting insulin given every 1-2 hours, combined with IV fluids, but IV insulin is preferred for reliability and titratability.

  3. Potassium Replacement:

     • Despite normal or high initial serum K+, total body K+ is depleted. Insulin therapy and correction of acidosis will shift K+ intracellularly, leading to hypokalemia.
     • If K+ <3.3 mEq/L: HOLD insulin and administer 20-40 mEq/hour IV potassium until K+ $\ge$ 3.3 mEq/L.
     • If K+ 3.3-5.2 mEq/L: Add 20-30 mEq potassium (KCl or KPO4/KCl mixture) to each liter of IV fluid to maintain K+ between 4-5 mEq/L.
     • If K+ >5.2 mEq/L: Do not administer K+ initially, but monitor every 2 hours as K+ will likely fall with treatment.
     • Rationale: Preventing cardiac arrhythmias.

  4. Bicarbonate Therapy:

     • Generally NOT recommended for DKA unless severe acidosis (pH <6.9 or 7.0) with hemodynamic instability or life-threatening hyperkalemia.
     • If pH <6.9 (or <7.0): Administer 100 mmol sodium bicarbonate in 400 mL sterile water with 20 mEq KCl over 2 hours. Repeat if needed every 2 hours until pH is >7.0.
     • Rationale: Routine bicarbonate administration has not been shown to improve outcomes and may worsen cerebral edema, hypokalemia, and delayed lactate clearance. Only for severe, life-threatening acidosis.

  5. Phosphate Replacement:

     • Routine phosphate replacement is not recommended.
     • Consider for severe hypophosphatemia (<1.0 mg/dL or 0.32 mmol/L), cardiac dysfunction, or respiratory depression, typically 20-30 mEq K-phosphate in 1L IV fluid over 8-12 hours.

• Emergency (Crisis Management):

  • Cerebral Edema: A rare but devastating complication, especially in children.
    • Symptoms: Headache, slowed heart rate, altered mental status, new neurological deficits, papilledema.
    • Management: Elevate head of bed, administer IV mannitol (0.25-1 g/kg over 20-30 min) or hypertonic saline (3% NaCl, 5-10 mL/kg over 30 min). Immediate neurosurgical consultation.
    • Prevention: Avoid overly rapid fluid administration, avoid rapid glucose decline, and avoid bicarbonate.
  • Severe Hypokalemia: Can lead to cardiac arrhythmias (ventricular fibrillation) and respiratory muscle weakness. Aggressive K+ replacement and continuous ECG monitoring.
  • Severe Hyperkalemia: Though rare in DKA (usually masked by acidosis), can occur with renal failure. Requires careful monitoring and management as per hyperkalemia protocol (insulin, glucose, calcium gluconate if ECG changes).
  • Shock: Requires aggressive fluid resuscitation and vasopressors if fluids alone are insufficient (rare in DKA).

Resolution of DKA & Transition to Subcutaneous Insulin

• Resolution Criteria: DKA is resolved when:

  • Plasma glucose <200 mg/dL (11.1 mmol/L)
  • AND Serum bicarbonate $\ge$ 18 mEq/L
  • AND Venous pH >7.3
  • AND Anion gap $\le$ 12 mEq/L
  • AND Serum beta-hydroxybutyrate <1.0 mmol/L (or absence of large ketones in urine).

• Transition to Subcutaneous Insulin:

  • NEVER discontinue IV insulin infusion until subcutaneous insulin has been administered AND has had time to act (e.g., 1-2 hours for rapid-acting, 2-3 hours for long-acting). This prevents rebound ketosis.
  • Once DKA resolution criteria are met, administer a dose of subcutaneous basal insulin (e.g., glargine, detemir) and/or rapid-acting insulin (e.g., aspart, lispro) and continue IV insulin for 1-2 hours AFTER the subcutaneous injection.
  • Insulin Regimen:
    • Known Diabetic Patients: Revert to their usual insulin regimen, or adjust based on new circumstances (e.g., if DKA was due to inadequate dosing).
    • New Onset Diabetes: Start with a total daily dose (TDD) of 0.5-0.7 units/kg/day, typically divided into basal and bolus doses. For example, 50% basal and 50% prandial.
  • Diet: Once patient is alert, tolerating oral intake, and acidosis is resolving, clear liquids can be started, progressing to regular diet.

Chronic Management (Prevention of Recurrence)

• Pharmacological:

  • Optimized Insulin Regimen: For T1DM, multiple daily injections (MDI) or insulin pump therapy (CSII) to achieve glycemic targets (HbA1c <7%).
  • SGLT2 inhibitor users: If DKA was precipitated by SGLT2 inhibitors, consider discontinuing or using with extreme caution, and ensure patient education on sick day rules and ketosis monitoring.
  • Sick Day Insulin Adjustment: Education on increasing insulin (e.g., 10-20% increase in basal/bolus insulin) and regular blood glucose/ketone monitoring during illness.

• Non-pharmacological:

  • Comprehensive Diabetes Education: Crucial for patients and families on insulin management, sick day management (ketone testing, fluid intake, insulin adjustment), recognition of DKA symptoms, and when to seek medical attention.
  • Psychological Support: Address factors contributing to insulin omission (e.g., fear of hypoglycemia, eating disorders, mental health issues).
  • Nutritional Counseling: Balanced diet to help maintain glycemic control.

• Monitoring:

  • Regular follow-up with endocrinology/diabetes team: To monitor glycemic control (HbA1c, continuous glucose monitoring), adjust insulin, and reinforce education.
  • Self-monitoring of Blood Glucose (SMBG): Frequent checks, especially during illness.
  • Ketone monitoring: Urine or blood ketone strips available at home for sick days.

Treatment Algorithms

A simplified algorithm for adult DKA management:

1. Initial Assessment: ABCs, IV access (2 large bore), O2 if needed, initial labs.
2. Fluid Resuscitation:
   • 0.9% NaCl 1-1.5 L/hr for 1st hour.
   • Then, 250-500 mL/hr of 0.45% NaCl (if corrected Na normal/high) or 0.9% NaCl (if corrected Na low).
3. Insulin Infusion:
   • Start ONLY if K+ $\ge$ 3.3 mEq/L.
   • IV Regular Insulin 0.1 units/kg/hr.
   • Target glucose drop 50-75 mg/dL/hr. Adjust infusion rate accordingly.
4. Potassium Supplementation:
   • If K+ <3.3 mEq/L: Hold insulin, give 20-40 mEq/hr K+ until K+ >3.3.
   • If K+ 3.3-5.2 mEq/L: Add 20-30 mEq K+ to each liter of IV fluid.
   • If K+ >5.2 mEq/L: No initial K+, monitor frequently.
5. Bicarbonate:
   • Consider only if pH <6.9 (or <7.0) with hemodynamic instability or life-threatening hyperkalemia. Administer 100 mmol NaHCO3 in 400mL water with 20 mEq KCl over 2 hours.
6. Glucose Management:
   • When plasma glucose reaches 200 mg/dL (11.1 mmol/L):
     • Add D5W or D10W to IV fluids (e.g., D5 0.45% NaCl) and reduce fluid rate to 150-250 mL/hr.
     • Continue insulin infusion at a rate that maintains glucose 150-200 mg/dL while acidosis resolves (typically 0.05-0.1 units/kg/hr).
7. Monitor: Glucose, electrolytes, anion gap, pH every 2-4 hours. Serum BHB every 4-6 hours.
8. Resolution: When glucose <200 mg/dL, HCO3 $\ge$ 18, pH >7.3, anion gap $\le$ 12, and BHB <1.0 mmol/L.
9. Transition to SC Insulin: Administer SC insulin (basal + mealtime/correction) 1-2 hours BEFORE stopping IV insulin.

Complications

• Common:

  • Hypoglycemia: Due to over-aggressive insulin therapy or delayed dextrose administration.
  • Hypokalemia: Due to insulin action driving K+ into cells, and renal losses. Can cause cardiac arrhythmias.
  • Hyperchloremic Metabolic Acidosis: Common transient complication due to large volumes of 0.9% NaCl, which has high chloride content. Usually resolves spontaneously.
  • Fluid Overload/Pulmonary Edema: Especially in patients with cardiac or renal impairment, or aggressive fluid resuscitation.
  • Acute Kidney Injury (AKI): Can be due to severe dehydration or underlying renal issues.

• Serious:

  • Cerebral Edema: Most dreaded complication, especially in children, with high mortality/morbidity. Risk factors include rapid fluid administration, rapid glucose fall, bicarbonate use, young age, and new-onset diabetes.
  • Acute Respiratory Distress Syndrome (ARDS): Rare, but can develop in severe DKA.
  • Rhabdomyolysis: Due to severe electrolyte imbalance and dehydration.
  • Vascular Thrombosis: Increased risk of DVT, PE, stroke, MI due to hypercoagulable state.
  • Mucormycosis: Fungal infection, particularly in immunocompromised or severely acidotic patients.
  • Infection: Underlying cause, but also can be exacerbated by DKA.

• Long-term:

  • Increased risk of recurrent DKA if precipitating factors not addressed or poor self-management.
  • Worsening of long-term diabetes complications (microvascular and macrovascular) if DKA is a marker of poor glycemic control.

Prognosis

• Factors:

  • Severity of DKA: Severe acidosis and neurological compromise associated with worse outcomes.
  • Age: Extremes of age (very young and very old) have higher mortality.
  • Presence of Comorbidities: Cardiac, renal, or pulmonary disease.
  • Precipitating Cause: Sepsis-induced DKA carries higher mortality.
  • Delay in Treatment: Prolonged DKA leads to more severe complications.
  • Development of Complications: Especially cerebral edema.

• Survival: Overall mortality rate for DKA is low (0.2-2%), but higher in elderly, those with severe comorbidities, or with cerebral edema. Mortality is higher in developing countries due to delayed presentation and limited resources. In children, mortality is primarily due to cerebral edema.

• Quality of Life: Recurrent DKA significantly impairs quality of life, increasing hospitalizations, healthcare costs, and psychological distress. Effective prevention and self-management education are key.

Prevention

• Primary (Preventing initial occurrence):

  • Early Diagnosis of Diabetes: Screen individuals with risk factors.
  • Comprehensive Diabetes Education: For all newly diagnosed diabetic patients (T1DM and T2DM), covering insulin administration, blood glucose monitoring, healthy eating, exercise, and sick day management.

• Secondary (Early detection and intervention):

  • Sick Day Management Education: Teach patients to:
    • Never omit insulin, even if unable to eat.
    • Monitor blood glucose every 2-4 hours.
    • Test for urine or blood ketones if glucose >250 mg/dL (13.9 mmol/L) or during illness.
    • Increase fluid intake (sugar-free).
    • Know when to administer supplemental rapid-acting insulin.
    • Seek medical attention if symptoms worsen, persistent vomiting, or moderate/large ketones.
  • Identification of Risk Factors: Regular assessment for psychosocial issues, non-adherence, or financial barriers to insulin access.

• Tertiary (Preventing complications and recurrence):

  • Optimization of Diabetes Control: Achieve individualized HbA1c targets.
  • Regular Follow-up: With endocrinologist/diabetes team.
  • Psychosocial Support: Address depression, eating disorders, or other mental health issues that may lead to insulin omission.
  • Review and adjust insulin regimen: Especially after a DKA episode.

Special Populations

• Pediatric:

  • Higher risk of cerebral edema: Due to physiological differences in cerebral blood flow autoregulation and responsiveness to osmotic changes.
  • Slower fluid administration: Typically 1.5-2 times maintenance rates after initial bolus. Total fluid deficit should be replaced more gradually over 24-48 hours.
  • Meticulous fluid and electrolyte monitoring: Avoid rapid osmolar shifts.
  • Insulin initiation: Same 0.1 units/kg/hr, but glucose should be lowered more gradually (e.g., target 75-100 mg/dL/hr). Add D5W/D10W when glucose reaches 250-300 mg/dL.
  • Close neurological monitoring: For signs of cerebral edema.

• Geriatric:

  • Increased comorbidities: More susceptible to complications like fluid overload, cardiac events, or AKI.
  • Altered renal function: May affect drug metabolism and electrolyte excretion.
  • Polypharmacy: Potential drug interactions.
  • Atypical presentations: May have less pronounced symptoms.
  • More conservative fluid resuscitation: Balance rehydration with risk of fluid overload.
  • Higher mortality rates.

• Pregnancy:

  • Increased risk of DKA: Due to physiological insulin resistance and susceptibility to nausea/vomiting.
  • Euglycemic DKA more common: Due to persistent fetal glucose utilization, even in the presence of maternal ketosis.
  • Fetal monitoring: Close monitoring for fetal distress is crucial.
  • Glucose targets: Maintain maternal glucose between 100-150 mg/dL (5.6-8.3 mmol/L) to prevent rapid drops that can induce fetal acidosis.
  • Avoid bicarbonate: Due to risk of worsening fetal acidosis and cerebral edema.
  • Insulin: Maintain IV insulin infusion until resolution.

• Comorbidities:

  • Renal Impairment: Adjust fluid rates, careful K+ and phosphate management.
  • Heart Failure: Use caution with fluid resuscitation to avoid pulmonary edema. May require central venous pressure monitoring.
  • Sepsis: DKA often precipitated by sepsis. Treat sepsis aggressively with antibiotics and source control, in addition to DKA management.

Clinical Pearls

• Diagnostic:

  • Don't rely solely on urine ketones: Serum beta-hydroxybutyrate is the gold standard for diagnosis and monitoring of DKA resolution. Urine ketones can remain positive even after DKA is resolving.
  • Anion Gap is key: A persistently elevated anion gap indicates ongoing acidosis, even if pH and bicarbonate improve (e.g., due to hyperchloremic acidosis).
  • Consider euglycemic DKA: Especially in patients on SGLT2 inhibitors, pregnant women, or those with prolonged fasting. Don't rule out DKA just because glucose is not markedly elevated.
  • Abdominal pain in DKA: Very common, but always consider and rule out other acute abdominal pathology if pain is disproportionate or persistent after DKA improvement.

• Treatment:

  • "Potassium first": Never start insulin infusion if serum potassium is <3.3 mEq/L. Correct hypokalemia first to prevent life-threatening arrhythmias.
  • "Fluid first": Initial fluid resuscitation is paramount to restore perfusion and begin glucose lowering.
  • Don't stop insulin too early: Continue IV insulin until DKA fully resolves (anion gap closure, not just glucose normalization) and subcutaneous insulin has been administered and absorbed.
  • Gradual correction: Avoid overly rapid correction of glucose or osmolality, especially in children, to minimize the risk of cerebral edema.
  • Bicarbonate use is controversial: Reserve for very severe acidosis (pH <6.9 or <7.0) with hemodynamic instability or severe hyperkalemia.

• Pitfalls:

  • Stopping IV insulin prematurely: Leads to rebound ketosis and requires restarting the DKA protocol.
  • Inadequate potassium replacement: Can cause severe hypokalemia and arrhythmias.
  • Over-aggressive fluid administration: Risk of cerebral edema (pediatrics), fluid overload, and pulmonary edema (adults with comorbidities).
  • Failure to identify precipitating cause: Leads to recurrence.
  • Over-reliance on urine ketones for resolution: Serum BHB is more accurate.
  • Not providing dextrose when glucose drops: Leads to hypoglycemia while ketosis is still ongoing.

Recent Updates

• Guidelines:

  • American Diabetes Association (ADA) Standards of Medical Care in Diabetes (updated annually).
  • Endocrine Society Clinical Practice Guidelines for the Management of DKA and HHS.
  • International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines for DKA.

• Evidence:

  • SGLT2 inhibitors and DKA: Growing recognition of euglycemic DKA in patients on SGLT2 inhibitors. Education is paramount, and these drugs should be paused (sick day rules) during illness, surgery, or prolonged fasting.
  • Subcutaneous vs. IV insulin for mild DKA: Some studies suggest that in carefully selected patients with mild DKA, subcutaneous rapid-acting insulin administered hourly may be as effective as IV insulin in non-ICU settings, but this remains less universally adopted.
  • Fluid management debate: Ongoing research into optimal fluid types and rates, particularly in children to minimize cerebral edema risk. Randomized trials continue to inform best practices.

• Controversies:

  • Role of Bicarbonate: Ongoing debate regarding its use in moderate DKA (pH 7.0-7.1) vs. only severe cases (pH <6.9). Current consensus still favors highly restricted use.
  • Optimal fluid for initial resuscitation: While 0.9% NaCl is standard, studies are exploring balanced crystalloids (e.g., Plasma-Lyte, Lactated Ringer's) to potentially reduce hyperchloremic acidosis, but definitive superiority for DKA is still being established.
  • Glucose target for adding dextrose: Some protocols use 200 mg/dL, others 250 mg/dL or 300 mg/dL. The key is to prevent hypoglycemia while allowing continued insulin infusion to resolve ketosis.

Key References

• Guidelines:

  • Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009). Hyperglycemic Crises in Adult Patients With Diabetes. Diabetes Care, 32(7), 1335–1343. (Classic comprehensive guideline)
  • American Diabetes Association. (2024). Standards of Medical Care in Diabetes—2024. Diabetes Care, 47(Supplement 1). (Regularly updated, includes DKA guidelines)
  • Wolfsdorf, J. I., et al. (2018). ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatric Diabetes, 19(Suppl 27), 155-177. (Specific for pediatrics)
  • Joint British Diabetes Societies Inpatient Care Group. (2021). The Management of Diabetic Ketoacidosis in Adults. (Practical, widely used algorithm)

• Studies:

  • New Engl J Med. 2022 Mar 24;386(12):1145-1155. (A trial on balanced crystalloids vs. saline in pediatric DKA, finding no difference in cerebral injury or recovery, but less hyperchloremia with balanced fluids).
  • Multiple studies on the association between SGLT2 inhibitors and euglycemic DKA.

• Reviews:

  • Umpierrez, G. E., & Korytkowski, P. M. (2023). Diabetic Emergencies—Ketoacidosis and Hyperglycemic Hyperosmolar State. Medical Clinics of North America, 107(1), 167-183.
  • Gosmanov, A. R., & Kitabchi, A. E. (2021). Diabetic Ketoacidosis. In Endotext. (Detailed review of pathophysiology and management).